Genenta Science S.p.A.
NCM: GNTALive Quote
📈 ZcoreAI Score
Our AI model analyzes Genenta Science S.p.A.'s price action across multiple timeframes using regression channels and statistical scoring.
Get GNTA Z-Score →About Genenta Science S.p.A.
Healthcare
Biotechnology
Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. Its lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter. The company is developing Temferon for use in the treatment of other solid tumor indications, locally advanced hepatocellular carcinoma, and intra-hepatic cholangiocarcinoma. In addition, it develops biologic platform to deliver immunomodulatory molecules directly to the tumor by infiltrating monocytes/macrophages. The company was incorporated in 2014 and is headquartered in Milan, Italy.
📊 Fundamental Analysis
Genenta Science S.p.A. demonstrates a profit margin of 0.0%, which is below the sector average, suggesting competitive pressure.
Return on Equity (ROE) is -38.0%, which indicates that capital utilization is currently under pressure.
At a current price of $0.67, GNTA currently trades near the bottom of its 52-week range (1%), indicating potential value or weakness (Range: $0.59 - $10.00).
🏥 Financial Health
🔴
Profit Margin
Weak
✅
Debt/Equity
Excellent
🔴
Return on Equity
Weak
✅
Beta (Risk)
Low Volatility
Key Financials
Market Cap
$15.78M
Trailing P/E
--
Forward P/E
-1.03
Beta (5Y)
0.71
52W High
$10.00
52W Low
$0.59
Avg Volume
1.09M
Day High
Day Low